Standardized Elderberry Chokeberry Extract Composition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current preparations containing elderberry and chokeberry extracts lack standardization, leading to potential toxicity and adverse effects due to cyanogenic glycoside content, and there is no available complex preparation with proven immunomodulatory and antiviral activity on the market.
Innovation Solution
A pharmaceutical composition comprising a standardized mixture of elderberry (Sambucus nigra) and chokeberry (Aronia melanocarpa) extracts with a ratio of 2:1 to 1:2, containing 10-30% anthocyanins and 15-50% polyphenols, for oral administration, which is processed using selective water-based extraction and purification to ensure optimal active compound concentration and minimize side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If elderberry and chokeberry extracts are used in preparations, then antiviral and immunostimulatory effects are achieved, but cyanogenic glycoside content causes potential toxicity and adverse gastrointestinal effects
Solution Approach 1:
The patent applies extraction by isolating and removing cyanogenic glycosides from the elderberry and chokeberry extracts through purification processes. This selective removal eliminates the toxic component while retaining the beneficial antiviral and immunostimulatory compounds, directly resolving the contradiction between therapeutic effect and toxicity
Solution Approach 2:
The patent changes the concentration parameters of the extract components by standardizing the formulation to contain specific ranges of anthocyanins (10-30%) and polyphenols (15-50%) while minimizing cyanogenic glycosides. This parameter optimization ensures therapeutic efficacy while reducing toxicity to acceptable levels
2Device complexity
If non-standardized extracts are used, then preparation complexity is reduced, but antiviral efficacy and safety cannot be ensured
Solution Approach 1:
The patent establishes specific parameter ranges for active compounds (anthocyanins 10-30%, polyphenols 15-50%) and cyanogenic glycoside limits in the standardized extract. This quantification transforms the preparation from an unstandardized mixture to a controlled pharmaceutical composition with guaranteed efficacy and safety
Solution Approach 2:
The patent replaces empirical, experience-based extract preparation with a standardized analytical and purification system that uses chromatographic methods and spectroscopic analysis to ensure consistent quality. This substitution of mechanical/chemical systems for empirical methods ensures reproducible antiviral efficacy
3Reliability
If high concentrations of extracts are used to maximize antiviral effect, then viral replication inhibition is enhanced, but cytotoxicity and adverse effects increase
Solution Approach 1:
The patent removes cytotoxic components through purification while concentrating the antiviral active compounds. This selective extraction allows achieving high viral replication inhibition at lower overall extract concentrations, thereby reducing cytotoxicity
Solution Approach 2:
The patent creates a composition with non-uniform distribution of components, concentrating antiviral compounds (anthocyanins, polyphenols) while minimizing toxic components (cyanogenic glycosides) in specific regions of the formulation. This local quality optimization enhances antiviral effect while reducing harm
Data Source
AI summary
The subject of the invention is a pharmaceutical composition and preparation, which contains as an active ingredient a mixture of elderberry fruit extract Sambucus nigra and chokeberry fruit extract Aronia melanocarpa in a ratio of 2: 1 to 1:2. The subject of the invention is also the use of this composition/preparation for the manufacture of dietary supplements for use in supportive therapy in the treatment of diseases with a viral basis for internal use (administered orally).